Is Measuring C-Reactive Protein Useful for Guiding Treatment in Women ≥60 Years and Men ≥50 Years of Age?

American Journal of Cardiology

Volumn 104, Issue 3, 2009, Pages 354-358

  Muntner, Paul ^a   Mann, Devin ^a   Razzouk, Louai ^a   Klarenbach, Scott ^b   Manns, Braden ^c   Tonelli, Marcello ^b   Farkouh, Michael E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

AGED; C-REACTIVE PROTEIN; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 67651097953     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.03.048     Document Type: Article

References (17)

1. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto Jr. A.M., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., and Glynn R.J. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
2. Ford E.S., Giles W.H., Myers G.L., and Mannino D.M. Population distribution of high-sensitivity C-reactive protein among US men: findings from National Health and Nutrition Examination Survey 1999-2000. Clin Chem 49 (2003) 686-690
3. Ford E.S., Giles W.H., Mokdad A.H., and Myers G.L. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem 50 (2004) 574-581
4. National Center for Health Statistics. NHANES 2003-2004. http://www.cdc.gov/nchs/about/major/nhanes/nhanes2003-2004/nhanes03_04.htm Accessed September 1, 2006
5. National Center for Health Statistics. NHANES 2005-2006. http://www.cdc.gov/nchs/about/major/nhanes/nhanes2005-2006/nhanes05_06.htm Accessed November 19, 2008
6. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
7. Stevens L.A., Coresh J., Greene T., and Levey A.S. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354 (2006) 2473-2483
8. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
9. Wener M.H., Daum P.R., and McQuillan G.M. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol 27 (2000) 2351-2359
10. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
11. Bazzano L.A., He J., Muntner P., Vupputuri S., and Whelton P.K. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 138 (2003) 891-897
12. Ford E.S. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 22 (1999) 1971-1977
13. Ford E.S. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 168 (2003) 351-358
14. Muntner P., Hamm L.L., Kusek J.W., Chen J., Whelton P.K., and He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140 (2004) 9-17
15. Wald N.J., and Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326 (2003) 1419
16. Cohen D.E., Anania F.A., and Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 97 (2006) 77C-81C
17. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., and Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40 (2002) 567-572